Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TMR Endorsed For Some Ischemia Patients By Society Of Thoracic Surgeons

This article was originally published in The Gray Sheet

Executive Summary

Society of Thoracic Surgeons evidence-based 1guidelines on transmyocardial laser revascularization (TMR), released March 30, are the first clinical practice guidelines to be issued by the organization

You may also be interested in...



TMR During Coronary Bypass: CMS Convenes MCAC To Reconsider Coverage

CMS should gather more prospective clinical trial data on transmyocardial revascularization during cardiac bypass surgery (TMR + CABG) before considering changes to its TMR Medicare coverage policy, the Society of Thoracic Surgery argues

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020028

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel